EVENTIDE ASSET MANAGEMENT, LLC
Q3 2022 13F-HR Holdings
Net value change ($000)
+407,193
(8.7%)
New positions
18
Sold out positions
16
Turnover %
12.2%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q2 2022
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| BHVN | 74,894 | NEW |
| Prometheus Biosciences, Inc. | 66,254 | 72.6% |
| Horizon Therapeutics Public Ltd Co | 54,541 | 979.7% |
| DV | 50,519 | NEW |
| DOCS | 50,420 | 95.7% |
| XMTR | 44,078 | 92.5% |
| FLYW | 38,993 | 1664.2% |
| Karuna Therapeutics, Inc. | 38,536 | 49.2% |
| MDB | 35,099 | 157.3% |
| TTD | 33,032 | 43.2% |
Top Reduces (Value $000, Stocks/ETFs)
| Biohaven Pharmaceutical Holding Co Ltd. | -164,521 | -100.0% |
| DUOL | -33,127 | -100.0% |
| KURA | -32,813 | -100.0% |
| DICE Therapeutics, Inc. | -20,778 | -100.0% |
| NOVT | -19,396 | -57.1% |
| ChemoCentryx, Inc. | -18,049 | -100.0% |
| CGNX | -15,265 | -100.0% |
| NRIX | -14,621 | -100.0% |
| FIVN | -12,126 | -10.7% |
| TREX | -10,375 | -19.3% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|